LEAT

SEC source: 0001062993-17-004465 · form4.xml · derivative · entry 2

Macdonald Sean · CIK 0001553633 · Director · CEO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,000

Underlying: Common Stock, par value $0.001 per share · 78,000 shares

Expires 2026-03-28

F2 · shares: On March 29, 2016, the Issuer's Board of Directors approved a grant to the Reporting Person of a 10-year option to purchase another 78,000 shares of the Issuer's common stock at an exercise price of $2.60 a share under the Issuer's 2011 Plan, 23,400 of which immediately vested and another 23,400 of which vested on March 29, 2017. The remaining options to purchase 31,200 shares are scheduled to vest in equal parts on March 29, 2018 and 2019, respectively.

F2 · derivative.exercise_date: On March 29, 2016, the Issuer's Board of Directors approved a grant to the Reporting Person of a 10-year option to purchase another 78,000 shares of the Issuer's common stock at an exercise price of $2.60 a share under the Issuer's 2011 Plan, 23,400 of which immediately vested and another 23,400 of which vested on March 29, 2017. The remaining options to purchase 31,200 shares are scheduled to vest in equal parts on March 29, 2018 and 2019, respectively.

F2 · derivative.underlying_shares: On March 29, 2016, the Issuer's Board of Directors approved a grant to the Reporting Person of a 10-year option to purchase another 78,000 shares of the Issuer's common stock at an exercise price of $2.60 a share under the Issuer's 2011 Plan, 23,400 of which immediately vested and another 23,400 of which vested on March 29, 2017. The remaining options to purchase 31,200 shares are scheduled to vest in equal parts on March 29, 2018 and 2019, respectively.

F1 · balance_after: On February 1, 2012, the Issuer's Board of Directors approved a grant to the Reporting Person, of a 5-year option to purchase 1,950,000 shares of the Issuer's common stock at $0.04 per share under the Issuer's 2011 Plan. After giving effect to the Reverse Split, the Reporting Person had vested options to purchase 78,000 shares of the Company's common stock at $1.00 per share. On September 1, 2016, the Reporting Person exercised his option to purchase all 78,000 shares at an aggregate exercise price of $78,000. The purchase price was paid through a cashless transaction whereby the Issuer withheld 31,200 of the shares in lieu of cash payment and the Reporting person received the remaining 46,800 shares.

F2 · balance_after: On March 29, 2016, the Issuer's Board of Directors approved a grant to the Reporting Person of a 10-year option to purchase another 78,000 shares of the Issuer's common stock at an exercise price of $2.60 a share under the Issuer's 2011 Plan, 23,400 of which immediately vested and another 23,400 of which vested on March 29, 2017. The remaining options to purchase 31,200 shares are scheduled to vest in equal parts on March 29, 2018 and 2019, respectively.

SEC source: 0001062993-17-004459 · form4.xml · derivative · entry 2

Leatt Christopher James · CIK 0001553632 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock, par value $0.001 per share · 52,000 shares

Expires 2026-03-28

F3 · shares: On March 29, 2016, the Issuer's Board of Directors approved a grant to the Reporting Person of a 10-year option to purchase another 52,000 shares of the Issuer's common stock at an exercise price of $2.60 a share under the Issuer's 2011 Plan, 15,600 of which immediately vested and an additional 15,600 of which vested on March 29, 2017. The remaining options to purchase 20,800 shares are scheduled to vest in equal parts on March 29, 2018 and 2019, respectively.

F3 · derivative.underlying_shares: On March 29, 2016, the Issuer's Board of Directors approved a grant to the Reporting Person of a 10-year option to purchase another 52,000 shares of the Issuer's common stock at an exercise price of $2.60 a share under the Issuer's 2011 Plan, 15,600 of which immediately vested and an additional 15,600 of which vested on March 29, 2017. The remaining options to purchase 20,800 shares are scheduled to vest in equal parts on March 29, 2018 and 2019, respectively.

F4 · balance_after: Total derivative securities include options to purchase shares of the Issuer's common stock, held as at the transaction date, and 96,000 shares of the Issuer's preferred stock held by the Reporting Person, convertible to common stock at a rate of 1 share of common stock for each share of preferred stock.

SEC source: 0001062993-19-002015 · form4.xml · derivative · entry 2

Guzy Jeffrey J · CIK 0001415532 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock, par value $0.001 per share · 15,000 shares

Expires 2019-02-13

F2 · kind: On February 14, 2014, the Issuer's Board of Directors approved the grant to the Reporting Person, of a 5-year option to purchase 15,000 shares of the Issuer's common stock at an exercise price of $1.00 a share under the Issuer's 2011 Plan, all of which vested by February 14, 2017. On February 12, 2019, the Reporting Person exercised his options to purchase 15,000 shares of the Issuer's Common Stock.

F2 · shares: On February 14, 2014, the Issuer's Board of Directors approved the grant to the Reporting Person, of a 5-year option to purchase 15,000 shares of the Issuer's common stock at an exercise price of $1.00 a share under the Issuer's 2011 Plan, all of which vested by February 14, 2017. On February 12, 2019, the Reporting Person exercised his options to purchase 15,000 shares of the Issuer's Common Stock.

F2 · derivative.underlying_shares: On February 14, 2014, the Issuer's Board of Directors approved the grant to the Reporting Person, of a 5-year option to purchase 15,000 shares of the Issuer's common stock at an exercise price of $1.00 a share under the Issuer's 2011 Plan, all of which vested by February 14, 2017. On February 12, 2019, the Reporting Person exercised his options to purchase 15,000 shares of the Issuer's Common Stock.

F2 · balance_after: On February 14, 2014, the Issuer's Board of Directors approved the grant to the Reporting Person, of a 5-year option to purchase 15,000 shares of the Issuer's common stock at an exercise price of $1.00 a share under the Issuer's 2011 Plan, all of which vested by February 14, 2017. On February 12, 2019, the Reporting Person exercised his options to purchase 15,000 shares of the Issuer's Common Stock.